The EMA investigation comes after the Icelandic Medicines Agency flagged reports of suicidal thoughts and self-injury in patients taking Ozempic and Saxenda. Credit: mojo cp via Shutterstock.

The European Medicines Agency (EMA) is reviewing data on the potential effects of high-profile glucagon-like peptide-1 receptor agonists (GLP-1RAs), including Ozempic (semaglutide), Saxenda (liraglutide) and Wegovy (semaglutide) in causing suicidal thoughts and thoughts of self-harm.

The EMA has previously approved these drugs for weight loss and/or as treatments for type 2 diabetes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile 鈥� free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The comes after the Icelandic Medicines Agency flagged reports of suicidal thoughts and self-injury in patients taking Ozempic and Saxenda. Authorities are so far investigating 150 reports of possible cases of self-injury and suicidal thoughts.

Led by the (PRAC), the EMA evaluation aims to find if these symptoms are linked to the medicines themselves, are unrelated or caused by other underlying factors. The EMA reports that more than 20 million patients in the EU have so far used liraglutide and semaglutide.

GLP-1RAs are a rapidly growing class of drugs with 28 therapies currently being investigated in Phase III trials, according to GlobalData. These medicines work by activating glucagon-like peptide 1, which increases insulin secretion from the pancreas, leading to a reduction in blood sugar and weight loss effects. With the success of blockbuster drugs such as Ozempic and Mounjaro (tirzepatide), pharmaceutical giants such as , and are now rapidly developing clinical pipelines with their own GLP1RAs.

GlobalData reports that made approximately $8.4bn in global sales for Ozempic last year. The company predicts that global sales could increase to almost $11.6bn by the end of this year.

GlobalData is the parent company of Pharmaceutical Technology.

The EMA is conducting this review similar to a signal procedure. The regulator describes a signal as 鈥渁 new adverse event that is potentially caused by a medicine or a new aspect of a known adverse event that warrants further investigation鈥�. Currently, none of the EU drug labels for approved GLP-1RAs include information about any mental health-associated risks.

The EMA began the review of Ozempic on 3 July but has now extended it to include the entire class of GLP-1 receptor agonists. The agency plans to complete the review by November 2023.

The that one in four adolescents and nearly 60% of adults are overweight or obese in the WHO European region. WHO have released multiple action plans to mitigate the rising problem, but currently no member state is on track to meet the goal of stopping the rise in obesity by 2025.